{"id":49044,"date":"2025-11-26T16:13:22","date_gmt":"2025-11-26T08:13:22","guid":{"rendered":"https:\/\/flcube.com\/?p=49044"},"modified":"2025-11-26T16:13:23","modified_gmt":"2025-11-26T08:13:23","slug":"innovents-mazdutide-9mg-obesity-application-accepted-by-nmpa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49044","title":{"rendered":"Innovent&#8217;s mazdutide 9mg Obesity Application Accepted by NMPA"},"content":{"rendered":"\n<p><strong>Innovent Biologics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its supplementary application for <strong>mazdutide 9mg<\/strong> for long\u2011term weight management in adults with moderate to severe obesity, expanding the dual GCG\/GLP\u20111 agonist\u2019s dosing options for severe disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>mazdutide 9mg<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Innovent Biologics, Inc. (1801.HK)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplementary application (new dosage)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Long\u2011term weight management in adults with moderate to severe obesity<\/td><\/tr><tr><td><strong>Existing Approvals<\/strong><\/td><td>Chronic weight management (adjunct to diet\/exercise); glycemic control in T2D<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Accepted for review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Glucagon (GCG)\/GLP\u20111 dual receptor agonist<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>First domestic dual agonist<\/strong> with <strong>9mg high\u2011dose<\/strong> option specifically targeting severe obesity<\/li>\n\n\n\n<li><strong>Dosage Strategy:<\/strong> 2\u20114\u20116mg for broad overweight\/obese population; <strong>3\u20116\u20119mg for severely obese<\/strong><\/li>\n\n\n\n<li><strong>Clinical Value:<\/strong> Offers <strong>step\u2011up dosing<\/strong> to address varying disease severity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-glory-2-study\">Clinical Evidence \u2013 GLORY-2 Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>GLORY\u20112 (NCT06164873), Phase\u202f3 registration trial<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Chinese adults with moderate to severe obesity<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met with significant weight reduction<\/td><\/tr><tr><td><strong>Key Results (Week\u202f60)<\/strong><\/td><td>Mean weight reduction: <strong>18.55%<\/strong>; <strong>44.0%<\/strong> achieved \u226520% reduction<\/td><\/tr><tr><td><strong>Liver Fat<\/strong><\/td><td>Mean reduction: <strong>71.9%<\/strong><\/td><\/tr><tr><td><strong>Cardiometabolic<\/strong><\/td><td>Significant improvements in BP, lipids, uric acid, waist circumference<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Favorable profile; no new safety signals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Severe Obesity Patients<\/strong><\/td><td>&gt;15\u202fmillion adults<\/td><\/tr><tr><td><strong>GLP\u20111 Market Size<\/strong><\/td><td>\u00a525\u202fbillion (US$3.4\u202fbillion) in 2024<\/td><\/tr><tr><td><strong>Pricing (9mg)<\/strong><\/td><td>Expected \u00a5800\u20111,200\/month (20% premium vs. 6mg)<\/td><\/tr><tr><td><strong>Peak Sales Forecast<\/strong><\/td><td><strong>\u00a58\u201112\u202fbillion<\/strong> (US$1.1\u20111.6\u202fbillion) by 2030<\/td><\/tr><tr><td><strong>Competitive Edge:<\/strong> High\u2011dose 9mg offers <strong>superior efficacy<\/strong> for severe obesity vs. competitor standard doses<\/td><td><\/td><\/tr><tr><td><strong>Reimbursement Path:<\/strong> NRDL inclusion likely given disease burden and domestic innovation status<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding mazdutide 9mg\u2019s regulatory review, market potential, and commercial launch timeline. Actual results may differ materially due to risks including NMPA approval outcomes, competitive responses, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112500388_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025112500388_c.\"><\/object><a id=\"wp-block-file--media-082979ae-1660-43b1-b604-94ca21535441\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112500388_c.pdf\">2025112500388_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025112500388_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-082979ae-1660-43b1-b604-94ca21535441\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has accepted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49046,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[910,4361,198,38],"class_list":["post-49044","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-1801","tag-hot-targets","tag-innovent-biologics","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent&#039;s mazdutide 9mg Obesity Application Accepted by NMPA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its supplementary application for mazdutide 9mg for long\u2011term weight management in adults with moderate to severe obesity, expanding the dual GCG\/GLP\u20111 agonist\u2019s dosing options for severe disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49044\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent&#039;s mazdutide 9mg Obesity Application Accepted by NMPA\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its supplementary application for mazdutide 9mg for long\u2011term weight management in adults with moderate to severe obesity, expanding the dual GCG\/GLP\u20111 agonist\u2019s dosing options for severe disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49044\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T08:13:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T08:13:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2608.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent&#8217;s mazdutide 9mg Obesity Application Accepted by NMPA\",\"datePublished\":\"2025-11-26T08:13:22+00:00\",\"dateModified\":\"2025-11-26T08:13:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044\"},\"wordCount\":313,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2608.webp\",\"keywords\":[\"HKG: 1801\",\"Hot targets\",\"Innovent Biologics\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49044#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49044\",\"name\":\"Innovent's mazdutide 9mg Obesity Application Accepted by NMPA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2608.webp\",\"datePublished\":\"2025-11-26T08:13:22+00:00\",\"dateModified\":\"2025-11-26T08:13:23+00:00\",\"description\":\"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its supplementary application for mazdutide 9mg for long\u2011term weight management in adults with moderate to severe obesity, expanding the dual GCG\\\/GLP\u20111 agonist\u2019s dosing options for severe disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49044\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2608.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2608.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent's mazdutide 9mg Obesity Application Accepted by NMPA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49044#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent&#8217;s mazdutide 9mg Obesity Application Accepted by NMPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent's mazdutide 9mg Obesity Application Accepted by NMPA - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its supplementary application for mazdutide 9mg for long\u2011term weight management in adults with moderate to severe obesity, expanding the dual GCG\/GLP\u20111 agonist\u2019s dosing options for severe disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49044","og_locale":"en_US","og_type":"article","og_title":"Innovent's mazdutide 9mg Obesity Application Accepted by NMPA","og_description":"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its supplementary application for mazdutide 9mg for long\u2011term weight management in adults with moderate to severe obesity, expanding the dual GCG\/GLP\u20111 agonist\u2019s dosing options for severe disease.","og_url":"https:\/\/flcube.com\/?p=49044","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-26T08:13:22+00:00","article_modified_time":"2025-11-26T08:13:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2608.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49044#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49044"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent&#8217;s mazdutide 9mg Obesity Application Accepted by NMPA","datePublished":"2025-11-26T08:13:22+00:00","dateModified":"2025-11-26T08:13:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49044"},"wordCount":313,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49044#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2608.webp","keywords":["HKG: 1801","Hot targets","Innovent Biologics","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49044#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49044","url":"https:\/\/flcube.com\/?p=49044","name":"Innovent's mazdutide 9mg Obesity Application Accepted by NMPA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49044#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49044#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2608.webp","datePublished":"2025-11-26T08:13:22+00:00","dateModified":"2025-11-26T08:13:23+00:00","description":"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has accepted its supplementary application for mazdutide 9mg for long\u2011term weight management in adults with moderate to severe obesity, expanding the dual GCG\/GLP\u20111 agonist\u2019s dosing options for severe disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49044#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49044"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49044#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2608.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2608.webp","width":1080,"height":608,"caption":"Innovent's mazdutide 9mg Obesity Application Accepted by NMPA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49044#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent&#8217;s mazdutide 9mg Obesity Application Accepted by NMPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2608.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49044"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49044\/revisions"}],"predecessor-version":[{"id":49048,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49044\/revisions\/49048"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49046"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}